Explorers on the frontier of
At NGM, we are charting new paths and pushing beyond boundaries to discover and deliver medicines for people whose health and lives have been disrupted by disease.
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
December 7, 2022
We are advancing our broad and diverse pipeline of biologic drug candidates, all discovered in-house, with the goal of addressing large unmet medical needs in cancer and other diseases that impact the lives of millions around the world.
Meet Our Team
We are explorers — 200+ strong. We are awed by human biology, undaunted by difficult problems, committed to excellence, optimistic about what lies ahead and humbled by the privilege and responsibility of discovering and developing medicines for our fellow humans.